ClinicalTrials.gg
CompletedNCT01006265Updated Mar 30, 2025Results posted

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 2 interventional study of ACT-128800 Dose 1 and Placebo in Multiple Sclerosis, sponsored by Actelion. Completed at 115 sites in 23 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
78th of 879
464 · median 50
Started
2009
with 38 others
Phase 2
139 of 1,192
20 open now
Registered
216th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 78th largest by enrollment of the 879 interventional ones that give a count, is one of 39 that started in 2009, is one of 139 in phase 2, and was the 216th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males and females
  • Diagnosis of RRMS as defined by the revised (2005) McDonald Diagnostic Criteria for Multiple Sclerosis (MS).
  • Signed inform consent prior to initiation of any study-mandated procedure.

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of MS categorized as primary progressive or secondary progressive or progressive relapsing.
  • Patients currently treated for an disorder other than MS.
  • for MRI.
  • Ongoing bacterial, viral, or fungal infection.
  • History or presence of .

Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
464 participants (actual)

Study arms

  • Experimental
    ACT-128800 Dose 1

    ACT-128800 Dose 1

    Drug: ACT-128800 Dose 1

  • Experimental
    ACT-128800 Dose 2

    ACT-128800 Dose 2

    Drug: ACT-128800 Dose 2

  • Experimental
    ACT-128800 Dose 3

    ACT-128800 Dose 3

    Drug: ACT-128800 Dose 3

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • ACT-128800 (Dose 1) administered orally once daily

  • DrugPlacebo

    Matching placebo administered orally once daily

  • ACT-128800 (Dose 2) administered orally once daily

  • ACT-128800 (Dose 3) administered orally once daily

06

What researchers measure

Primary outcomes

  1. Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24

    Cumulative Number of new T1 gadolinium-enhancing (Gd+) lesions per year on magnetic resonance imaging (MRI) scan from Week 12 to Week 24 were reported. Negative binomial (NB) regression analysis on Per protocol analysis set and imputation was applied for the missing data. Here, MS signifies multiple sclerosis.

    Time frame: From Week 12 to 24

Secondary outcomes

  1. Annualized Confirmed Relapse Rate

    Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple Sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS)

    Time frame: Up to 24 weeks

  2. Number of Participants With First Confirmed Relapse as Assessed by Kaplan-Meier Estimate From Baseline to Week 24

    Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of MS, not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS). Kaplan-Meier estimate used for Outcome Measure analysis.

    Time frame: Baseline to Week 24

07

Results

Posted Jun 11, 2021
Limitations and caveats
No limitation was identified for this study.

Participant flow

Participant flow — Overall Study
MilestonePonesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlacebo
Started119116108121
Treated119114108121
Completed11310799116
Not completed6995
Withdrew: Lost to follow-up1010
Withdrew: Withdrawal by subject4755
Withdrew: Administrative reason1230

Outcome measures

PrimaryCumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24

Cumulative Number of new T1 gadolinium-enhancing (Gd+) lesions per year on magnetic resonance imaging (MRI) scan from Week 12 to Week 24 were reported. Negative binomial (NB) regression analysis on Per protocol analysis set and imputation was applied for the missing data. Here, MS signifies multiple sclerosis.

Time frame:
From Week 12 to 24
Reported as:
Mean · Lesions
Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24
LesionsPonesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlacebo
Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 241.4 ± 3.241.1 ± 1.963.5 ± 7.276.2 ± 13.42
Statistical analysis
  • Ponesimod 40 mg vs Placebo · Negative binomial regression model · p = <0.0001 · Treatment effect (rate ratio): 0.226 · 95% CI 0.133 to 0.384
  • Ponesimod 20 mg vs Placebo · Negative binomial regression model · p = <0.0001 · Treatment effect (rate ratio): 0.170 · 95% CI 0.100 to 0.289
  • Ponesimod 10 mg vs Placebo · Negative binomial regression model · p = 0.0318 · Treatment effect (rate ratio): 0.566 · 95% CI 0.337 to 0.952
SecondaryAnnualized Confirmed Relapse Rate

Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple Sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS)

Time frame:
Up to 24 weeks
Reported as:
Mean · Relapse per year
Annualized Confirmed Relapse Rate
Relapse per yearPonesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlacebo
Annualized Confirmed Relapse Rate0.224 ± 0.78340.396 ± 1.01690.297 ± 0.79870.601 ± 1.6626
SecondaryNumber of Participants With First Confirmed Relapse as Assessed by Kaplan-Meier Estimate From Baseline to Week 24

Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of MS, not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS). Kaplan-Meier estimate used for Outcome Measure analysis.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Number of Participants With First Confirmed Relapse as Assessed by Kaplan-Meier Estimate From Baseline to Week 24
ParticipantsPonesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlacebo
Number of Participants With First Confirmed Relapse as Assessed by Kaplan-Meier Estimate From Baseline to Week 2410171425

Adverse events

Collected over Up to 29 weeks (AEs for Treatment duration (24 weeks) and follow up (5 Weeks) on Day 7 and Day 30 after last dose). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ponesimod 40 mg0/119 (0%)3/119 (2.5%)83/119 (69.7%)
Ponesimod 20 mg0/114 (0%)7/114 (6.1%)73/114 (64%)
Ponesimod 10 mg0/108 (0%)7/108 (6.5%)69/108 (63.9%)
Placebo0/121 (0%)5/121 (4.1%)77/121 (63.6%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPonesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlacebo
Atrioventricular Block Second DegreeCardiac disorders0/1191/1142/1080/121
Macular OedemaEye disorders0/1192/1140/1080/121
Coronary Artery DiseaseCardiac disorders0/1190/1141/1080/121
VertigoEar and labyrinth disorders0/1190/1141/1080/121
PyrexiaGeneral disorders0/1190/1141/1080/121
Alanine Aminotransferase IncreasedInvestigations0/1190/1141/1080/121
Aspartate Aminotransferase IncreasedInvestigations0/1190/1141/1080/121
Electrocardiogram QT ProlongedInvestigations0/1190/1141/1080/121
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1190/1141/1080/121
SomnolenceNervous system disorders0/1190/1141/1080/121
Most frequent other events
Showing 10 of 55
Most frequent other events
EventPonesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlacebo
HeadacheNervous system disorders15/11916/11415/10818/121
NasopharyngitisInfections and infestations13/11912/11416/10817/121
DyspnoeaRespiratory, thoracic and mediastinal disorders16/1197/1145/1084/121
Oedema PeripheralGeneral disorders13/1193/1142/1082/121
Disease ProgressionGeneral disorders11/1199/11410/1086/121
Upper Respiratory Tract InfectionInfections and infestations11/1199/1144/10811/121
DizzinessNervous system disorders11/1197/1148/1083/121
FatigueGeneral disorders6/1199/1147/1087/121
CoughRespiratory, thoracic and mediastinal disorders8/1193/1141/1082/121
DiarrhoeaGastrointestinal disorders3/1193/1143/1088/121

Baseline characteristics

All-randomized analysis set included all randomized participants, whether or not they received study drug.

Age, Continuous
Age, Continuous(years)Ponesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlaceboTotal
Age ( years )36.5 ± 8.5235.3 ± 8.5236.9 ± 9.2436.6 ± 8.5836.3 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Ponesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlaceboTotal
Gender — Female79787185313
Gender — Male40383736151
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ponesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlaceboTotal
Hispanic or Latino20002
Not Hispanic or Latino00000
Unknown or Not Reported117116108121462
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ponesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlaceboTotal
American Indian or Alaska Native00011
Asian10102
Native Hawaiian or Other Pacific Islander00000
Black or African American222612
White114114105114447
More than one race00000
Unknown or Not Reported20002
Region of Enrollment
Region of Enrollment(Participants)Ponesimod 40 mgPonesimod 20 mgPonesimod 10 mgPlaceboTotal
Australia01001
Austria22239
Belgium20002
Bulgaria545519
Canada334313
Finland644620
Czech Republic1414121252
France11114
Germany12126
Hungary772319
Israel32139
Italy876728
Netherlands11226
Poland78101237
Romania12339
Russia998733
Spain423413
Serbia1010111142
Sweden564621
Switzerland02215
United Kingdom554418
Ukraine565723
United States2018181975
08

Study locations

115 sites
  • Clinical Investigative Site 3132
    Scottsdale, Arizona 85259, United States
  • Clinical Investigative Site 3100
    Tucson, Arizona 85741, United States
  • Clinical Investigative Site 3115
    Sacramento, California 95817, United States
  • Clinical Investigative Site 3117
    Stanford, California 94305, United States
  • Clinical Invesigative Site 3116
    Sarasota, Florida 34233, United States
  • Clinical Investigative Site 3101
    Indianapolis, Indiana 46202, United States
  • Clinical Investigative Site 3105
    Kansas City, Kansas 66160, United States
  • Clinical Investigative Site 3107
    Lenexa, Kansas 66214, United States
  • Clinical Investigative Site 3118
    Baltimore, Maryland 21201, United States
  • Clinical Investigative Site 3133
    Worcester, Massachusetts 01605, United States
  • Clinical Investigator 3136
    Saint Louis, Missouri 63100, United States
  • Clinical Investigative Site # 3135
    Newark, New Jersey 07103, United States
  • Clinical Investigative Site 3129
    Latham, New York 12110, United States
  • Clinical Investigative Site # 3128
    New York, New York 10032, United States
  • Clinical Investigative Site 3127
    Schenectady, New York 12308, United States
  • Clinical Investigative Site 3120
    Stony Brook, New York 11794, United States
  • Clinical Investigative Site 3119
    Raleigh, North Carolina 27607, United States
  • Clinical Investigator 3126
    Akron, Ohio 44320, United States
  • Clinical Investigative Site 3113
    Cincinnati, Ohio 45219, United States
  • Clinical Investigative Site 3130
    Columbus, Ohio 43221, United States
  • Clinical Investigator 3104
    Portland, Oregon 97225, United States
  • Clinical Investigative Site 3125
    Philadelphia, Pennsylvania 19107, United States
  • Clinical Investigative Site 3112
    Burlington, Vermont 05401, United States
  • Clinical Investigative Site 3111
    Richmond, Virginia 23298, United States
  • Clinical Investigative Site 3102
    Kirkland, Washington 98034, United States
  • Clinical Investigative Site # 1001
    Fitzroy, 3065, Australia
  • Clinical Investigative Site 1000
    Westmead, 2145, Australia
  • Clinical Investigative Site 1102
    Amstetten, 3300, Austria
  • Clinical Investigative Site 1100
    St Polten, 3100, Austria
  • Clinical Investigative Site 1101
    Vienna, 1090, Austria
  • Clinical Investigative Site 1201
    La Louviere, 7100, Belgium
  • Clinical Investigative Site # 1205
    Liege, 4000, Belgium
  • Clinical Investigative Site 1204
    Ottignies, 1340, Belgium
  • Clinical Investigative Site 1203
    Sijsele-Damme, 8340, Belgium
  • Clinical Investigative Site 1302
    Sofia, 1309, Bulgaria
  • Clinical Investigative Site 1301
    Sofia, 1431, Bulgaria
  • Clinical Investigative Site 1303
    Varna, 9010, Bulgaria
  • Clinical Investigative Site 1304
    Varna, 9010, Bulgaria
  • Clinical Investigative Site 1401
    Burbaby, British Columbia V5G 2X6, Canada
  • Clinical Investigative Site # 1401
    Burnaby, V5G 2X6, Canada
  • Clinical Investigative Site 1400
    Ottawa, K1H 8L6, Canada
  • Clinical Investigative Site 1502
    Brno, 656 91, Czechia
  • Clinical Investigative Site 1506
    Jihlava, 586 33, Czechia
  • Clinical Investigative Site 1504
    Olomouc, 775 20, Czechia
  • Clinical Investigative Site 1501
    Ostrava-Poruba, 70852, Czechia
  • Clinical Investigative Site 1500
    Praha, 128 08, Czechia
  • Clinical Investigative Site 1503
    Teplice, Czechia
  • Clinical Investigative Site 1600
    Helsinki, 00100, Finland
  • Clinical Investigative Site 1601
    Hyvinkaa, 05800, Finland
  • Clinical Investigative Site 1603
    Tampere, 33520, Finland
  • Clinical Investigative Site 1602
    Turku, 20100, Finland
  • Clinical Investigative Site 1701
    Montpellier Cedex, 34295, France
  • Clinical Investigative Site # 1806
    Bayreuth, 95445, Germany
  • Clinical Investigative 1807
    Berlin, 10117, Germany
  • Clinical Investigative Site 1803
    Berlin, 13347, Germany
  • Clinical Investigative site 1800
    Dusseldorf, 40225, Germany
  • Clinical Investigative Site 1802
    Essen, 45147, Germany
  • Clinical Investigative Site 1805
    Homburg/Saar, 66421, Germany
  • Clinical Investigative Site 1804
    Ulm, 89081, Germany
  • Clinical Investigative Site 1905
    Budapest, 1134, Hungary
  • Clinical Investigative Site # 1904
    Budapest, H-1115, Hungary
  • Clinical Investigative Site 1908
    Budapest, H-1145, Hungary
  • Clinical Investigative Site 1902
    Gyor, 11-9024, Hungary
  • Clinical Investigative Site 1900
    Petofi, 2500, Hungary
  • Clinical Investigative Site 1901
    Szentpeteri-Kapu, 3526, Hungary
  • Clinical Investigative Site 2000
    Ashkelon, 78278, Israel
  • Clinical Investigative Site 2003
    Tel-Aviv, 64239, Israel
  • Clinical Investigative Site 2001
    Tel-Hashomer, 52621, Israel
  • Clinical Investigative Site 2002
    Zerifin, 70300, Israel
  • Clinical Investigative Site 2101
    Gallarte, 21013, Italy
  • Clinical Investigative Site 2104
    Genova, 16132, Italy
  • Clinical Investigative Site # 2106
    Milan, 20132, Italy
  • Clinical Investigative Site 2102
    Padova, 35128, Italy
  • Clinical Investigative Site 2103
    Roma, 00189, Italy
  • Clinical Investigative Site 2105
    Siena, 53100, Italy
  • Clinical Investigative Site 2203
    Breda, 4818, Netherlands
  • Clinical Investigative Site 2202
    Nijmegen, 6533, Netherlands
  • Clinical Investigative Site 2201
    Sittard-Geleen, 6162, Netherlands
  • Clinical Investigative Site 2305
    Katowice, 47-752, Poland
  • Clinical Investigative Site 2303
    Poznan, 60-355, Poland
  • Clinical Investigative Site 2304
    Warsaw, 02-957, Poland
  • Clinical Investigative Site 2302
    Wroclaw, 50-044, Poland
  • Clinical Investigative Site 2400
    Bucuresti, 022903, Romania
  • Clinical Investigative Site 2401
    Cluj-Napoca, 428063, Romania
  • Clinical Investigative Site 2402
    Timisoara, 300736, Romania
  • Clinical Investigative Site # 3202
    Moscow, 127018, Russian Federation
  • Clinical Investigative Site # 3203
    Nizhniy Novgorod, 603155, Russian Federation
  • Clinical Investigative Site # 3206
    Pyatigorsk, 357538, Russian Federation
  • Clinical Investigative Site # 3201
    Samara, 443095, Russian Federation
  • Clinical Investigative Site 3209
    Saratov, 410030, Russian Federation
  • Clinical Investigative Site # 3204
    St. Petersburg, 194354, Russian Federation
  • Clinical Investigative Site 3201
    St. Petersburg, 197022, Russian Federation
  • Clinical Investigative Site 3200
    St. Petersburg, 197376, Russian Federation
  • Clinical Investigative Site 3208
    Ufa, 450005, Russian Federation
  • Clinical Investigative Site 2501
    Belgrade, 11000, Serbia
  • Clinical Investigative Site 2503
    Kragujevac, 34000, Serbia
  • Clinical Investigative Site 2502
    Nis, 18000, Serbia
  • Clinical Investigative Site 2706
    Barcelona, 08035, Spain
  • Clinical Investigative Site 2702
    Madrid, 28040, Spain
  • Clinical Investigative Site 2705
    Madrid, 28222, Spain

Showing the first 100 of 115 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21. PubMed 24659797 ↗
  • Gisleskog PO, Valenzuela B, Scherz T, Burcklen M, Perez-Ruixo JJ, Poggesi I. An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. Clin Pharmacokinet. 2021 Sep;60(9):1227-1237. doi: 10.1007/s40262-021-01020-2. Epub 2021 Apr 29. PubMed 33914286 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Jun 2011, 20 months.

Results were first posted in Jun 2021, 10 years after primary completion. A results delay was requested in Sep 2012.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 20 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2009
First posted
Nov 1, 2009
StartActual
Oct 1, 2009
Primary completionActual
Jun 1, 2011
CompletionActual
Jul 1, 2011
Results delay requested
Sep 27, 2012
Results first posted
Jun 11, 2021
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01006265
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Nov 1, 2009
Start date
Oct 1, 2009
Primary completion
Jun 1, 2011
Completion
Jul 1, 2011
Results posted
Jun 11, 2021
Last update
Mar 30, 2025

Study contacts

Actelion Pharmaceuticals
study director · Actelion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion